Your browser is no longer supported. Please, upgrade your browser.
Settings
AKRX Akorn, Inc. daily Stock Chart
AKRX [NASD]
Akorn, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own1.60% Shs Outstand128.29M Perf Week3.87%
Market Cap860.83M Forward P/E14.34 EPS next Y0.47 Insider Trans0.00% Shs Float92.96M Perf Month-49.51%
Income-211.70M PEG- EPS next Q0.11 Inst Own78.60% Short Float8.48% Perf Quarter-60.18%
Sales763.50M P/S1.13 EPS this Y-128.00% Inst Trans-0.12% Short Ratio2.67 Perf Half Y-65.29%
Book/sh5.76 P/B1.16 EPS next Y6.36% ROA-9.70% Target Price8.00 Perf Year-79.80%
Cash/sh- P/C- EPS next 5Y15.00% ROE-22.70% 52W Range5.25 - 33.63 Perf YTD-79.18%
Dividend- P/FCF31.53 EPS past 5Y-26.90% ROI-0.60% 52W High-80.05% Beta2.51
Dividend %- Quick Ratio2.90 Sales past 5Y26.80% Gross Margin45.10% 52W Low27.81% ATR0.73
Employees2284 Current Ratio3.90 Sales Q/Q-4.10% Oper. Margin-29.30% RSI (14)25.57 Volatility6.86% 6.64%
OptionableYes Debt/Eq1.13 EPS Q/Q- Profit Margin-24.20% Rel Volume1.02 Prev Close6.26
ShortableYes LT Debt/Eq1.13 EarningsOct 31 BMO Payout- Avg Volume2.96M Price6.71
Recom2.90 SMA20-27.38% SMA50-50.42% SMA200-64.40% Volume3,009,821 Change7.19%
Jul-25-18Reiterated RBC Capital Mkts Sector Perform $25 → $27
Apr-25-17Downgrade Piper Jaffray Overweight → Neutral
Apr-25-17Downgrade Jefferies Buy → Hold
Apr-25-17Downgrade Gabelli & Co Buy → Hold
Mar-10-17Reiterated WallachBeth Hold $22 → $25
Dec-01-16Initiated Goldman Sell
Nov-07-16Downgrade WallachBeth Buy → Hold $40 → $22
Nov-07-16Downgrade BofA/Merrill Buy → Underperform
Nov-04-16Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $24
Sep-15-16Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated WallachBeth Buy $39 → $40
Aug-05-16Downgrade Deutsche Bank Buy → Hold $33 → $33
Aug-02-16Downgrade Raymond James Outperform → Mkt Perform
Mar-18-16Reiterated Deutsche Bank Buy $40 → $33
Feb-12-16Reiterated RBC Capital Mkts Outperform $52 → $37
Dec-02-15Upgrade Nomura Neutral → Buy
Sep-29-15Initiated Nomura Neutral
Sep-09-15Initiated JMP Securities Mkt Perform
Jul-21-15Initiated Susquehanna Neutral
Jun-03-15Initiated Raymond James Outperform $53
Oct-16-18 06:24PM  Akorn, Inc. -- Moody's downgrades Akorn to B3; outlook changed to developing Moody's +7.19%
08:42AM  Implied Volatility Surging for Akorn (AKRX) Stock Options Zacks
Oct-11-18 05:19PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders Business Wire
Oct-10-18 09:43AM  Akorn's Generic Drug For Inadequate Eye Lashes Receives FDA Nod Benzinga
07:22AM  Akorn's stock soars after FDA approves ANDA for hypotrichosis of eyelashes treatment MarketWatch
07:05AM  Akorn Receives Product Approval GlobeNewswire
Oct-01-18 04:49PM  Why Infinera, Akorn, and Cal-Maine Foods Slumped Today Motley Fool -58.71%
04:46PM  Akorn shares plummet after judge rules against Lake Forest drugmaker American City Business Journals
04:43PM  GE, Tesla and GM jump while Akorn plunges Associated Press
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg Video
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg
12:18PM  Trade pact lifts European shares while Italy extends slide Reuters
12:08PM  Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal Reuters
11:52AM  Here's Why Akorn Inc. Collapsed Today Motley Fool
09:42AM  Akorn stock set to drop nearly 50% after court supports Fresenius ending $4.3 bln merger MarketWatch
09:25AM  Akorn Comments on Delaware Chancery Court Ruling Business Wire
09:19AM  Judge says Fresenius can walk away from $4.8 bln Akorn deal Reuters
08:56AM  Judge rules for Fresenius in bid to end $4.8 bln Akorn deal Reuters
08:54AM  Fresenius shares jump on report of win in Akorn ruling Reuters
08:30AM  Akorn Plunges After Judge Backs Fresenius Exit From Deal Bloomberg
01:57AM  [$$] Court rules Fresenius can ditch $4.75bn Akorn deal Financial Times
Sep-13-18 09:35AM  Is Akorn (AKRX) a Suitable Stock for Value Investors Now? Zacks
09:30AM  AKRX vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Aug-28-18 06:50AM  Akorn Enters Oversold Territory Zacks
Aug-27-18 09:30AM  AKRX vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
08:48AM  Do Options Traders Know Something About Akorn (AKRX) Stock We Don't? Zacks
Aug-24-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Akorn ACCESSWIRE
Aug-23-18 04:33PM  Here's Why Akorn, Inc. Fell as Much as 24.1% Today Motley Fool -17.56%
Aug-01-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Jul-31-18 07:10AM  Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks ACCESSWIRE
Jul-30-18 08:00AM  Today's Research Reports on Trending Tickers: Aurora Cannabis and Akorn ACCESSWIRE
Jul-24-18 09:30AM  Oversold Biotechnology Companies ACCESSWIRE
Jul-13-18 08:39AM  Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session Zacks -6.77%
08:00AM  Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals ACCESSWIRE
Jul-12-18 01:35PM  Fresenius Had Testing Woes Similar to Akorn, Unit Head Says Bloomberg +7.80%
01:35PM  Fresenius Had Testing Issues Similar to Akorn's, Executive Says Bloomberg
Jul-11-18 09:27PM  Execution blocked after company objects to use of its drug Associated Press
Jul-10-18 02:43PM  Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal Bloomberg
09:28AM  Lax Drugmaker Computer Security Linked to Deal Cancellation Bloomberg
Jul-09-18 10:30AM  Akorn Was Warned About Problems Before Merger, Executive Says Bloomberg
09:30AM  TEVA or AKRX: Which Is the Better Value Stock Right Now? Zacks
Jun-25-18 07:10AM  Free Technical Research on Akorn and Three More Generic Drugs Equities ACCESSWIRE
Jun-04-18 09:10AM  Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation GlobeNewswire
Jun-01-18 08:35AM  Options Traders Expect Huge Moves in Akorn (AKRX) Stock Zacks
May-29-18 03:31PM  Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc. PR Newswire
May-18-18 04:57AM  Fresenius CEO defends cancelled Akorn deal Reuters
May-11-18 07:00AM  Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks ACCESSWIRE
May-08-18 10:57AM  Top 3 Companies Owned by Valeant Investopedia
May-07-18 12:20PM  DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX ACCESSWIRE
11:05AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
10:27AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 ACCESSWIRE
May-04-18 02:00PM  DEADLINE MONDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX) ACCESSWIRE
10:30AM  Pawar Law: Important May 7, 2018 Lead Plaintiff Deadline in Akorn, Inc. Class Action- AKRX ACCESSWIRE
10:07AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 12:30PM  MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE -7.81%
12:13PM  AKRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018 ACCESSWIRE
09:58AM  Fresenius sees Akorn lawsuit dragging on into 2019 Reuters
May-02-18 11:48PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX Business Wire -14.97%
04:39PM  Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn Reuters
03:34PM  Here's Why Akorn Inc Fell as Much as 16.4% Today Motley Fool
01:50PM  DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
12:01PM  Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn Reuters
11:45AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX ACCESSWIRE
10:34AM  Fresenius alleges "blatant fraud" at abandoned target Akorn Reuters
10:00AM  FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Akorn, Inc. (Nasdaq: AKRX) To Contact The Firm GlobeNewswire
09:55AM  Akorn Accused of Sending Phony Data to FDA on Antibiotic Bloomberg
May-01-18 07:46PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
05:25PM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX) ACCESSWIRE
03:54PM  Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action AKRX GlobeNewswire
Apr-30-18 02:45PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX ACCESSWIRE
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 GlobeNewswire
Apr-28-18 09:23AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX ACCESSWIRE
Apr-27-18 04:07PM  Why Akorn, Inc.'s Stock Is Up Big Today Motley Fool +6.91%
Apr-26-18 12:35PM  DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
Apr-25-18 03:15PM  AKRX EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018 ACCESSWIRE
02:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX ACCESSWIRE
10:50AM  Akorn, Inc. Reminder: Important May 7, 2018 Lead Plaintiff Deadline in Class Action - AKRX ACCESSWIRE
Apr-24-18 03:45PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 AKRX ACCESSWIRE
01:46PM  Lifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc., Facebook, Inc., IZEA Inc., MuleSoft, Inc., Solid Biosciences Inc., and Tableau Software, Inc. PR Newswire
11:35AM  IMPORTANT DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
10:28AM  AKORN, INC. INVESTOR ALERT:  Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of shareholders of Akorn, Inc. GlobeNewswire
Apr-23-18 05:29PM  AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Akorn, Inc.To Contact The Firm Business Wire -33.76%
04:33PM  Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today Motley Fool
04:31PM  Henry Schein and Vectren rise while Akorn and Alcoa tumble Associated Press
04:30PM  Akorn, Inc. -- Moody's changes Akorn's ratings review to direction uncertain Moody's
04:20PM  Akorn Shares Crash After Fresenius Walks Away From Merger Deal Investor's Business Daily
04:16PM  Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3% TheStreet.com
02:51PM  3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
02:23PM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX) GlobeNewswire
02:20PM  Akorn Files Complaint on Fresenius' Canceled Bid Investopedia
12:00PM  A Fallen Akorn Is Too Expensive for Fresenius Bloomberg
10:59AM  Jilted Akorn sues Fresenius over deal termination Reuters
10:41AM  Jilted Akorn sues Fresenius over deal termination Reuters
10:25AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 ACCESSWIRE
10:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX Business Wire
09:42AM  Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations TheStreet.com
08:59AM  Akorn files complaint against Fresenius for ending merger deal MarketWatch
08:59AM  Tencent Music Entertainment Is Said to Prepare IPO Bloomberg Video
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAPOOR JOHN N10% OwnerJan 25Option Exercise26.4116,555437,188519,616Jan 26 06:00 PM
KAPOOR JOHN N10% OwnerJan 25Sale32.6713,629445,259505,987Jan 26 06:00 PM
Tambi BrianDirectorNov 21Sale33.3515,100503,58551,075Nov 22 05:01 PM